MET inhibitors including capmatinib and tepotinib target MET exon 14 skipping mutations, while RET inhibitors such as selpercatinib and pralsetinib focus on RET gene fusions in NSCLC [20, 21]. Here, MET is linked to non-small cell lung carcinoma.